Ebook: Alzheimer’s and Parkinson’s Diseases: Recent Developments

This book represents the third in a series of International Conferences related to Alzheimer's (AD) and Parkinson's (PD) diseases. The first one took place in Eilat, Israel, in 1985; and the second one in Kyoto, Japan, in 1989. This book contains the full text of oral and poster presentations from the Third International Conference on Alzheimer's and Parkinson's Diseases: Recent Developments, held in Chicago, Illinois, U.S.A. on November 1-6, 1993. The Chicago Conference was attended by 270 participants. The Scientific Program was divided into nine oral sessions, a keynote presentation, and a poster session. The conference culminated in a Round Table Discussion involving all of the participants in the conference. The four and one-half day meeting served as an excellent medium for surveying the current status of clinical and preclinical developments in AD and PD. There were 59 oral presentations and 93 posters. This book incorporates a majority of both.

---

---

Content:
Front Matter....Pages i-xx
Visual Processing in Alzheimer’s Disease....Pages 1-11
Stereopsis in Alzheimer’s Disease: Measuring Binocular Eye Movement....Pages 13-17
Visual Cognition and Language Function in Alzheimer’s Disease....Pages 19-24
Variables Affecting Visuospatial Primary Memory Defect in Alzheimer’s Disease: Preliminary Data....Pages 25-28
Articulatory Deficits in Parkinson’s and Huntington’s Disease: An Acoustic Analysis....Pages 29-32
Alzheimer’s Disease and Parkinson’s Disease with Dementia: Comparison of Cortical Blood Flow Demonstrated by Three-Dimensional Surface Display....Pages 33-38
Correlation between Severity of Dementia and Decreased Cerebral Blood Flow in Alzheimer’s Disease and Senile Dementia of the Alzheimer’s Type....Pages 39-44
Cerebral Blood Flow at Rest and During Cognitive Activation in Patients with Moderate Dementia of Alzheimer’s Type....Pages 45-49
Usefulness of Monitoring Left Ventricular Function by an Ambulatory Radionuclide Detector (VEST) in Patients with Parkinson’s Disease and Postural Hypotension....Pages 51-54
Frontal Dysfunction and Memory Deficit in Depression and Parkinson’s Disease....Pages 55-61
Cellular Acetylcholine Receptor Expression in the Brain of Patients with Alzheimer’s and Parkinson’s Dementia....Pages 63-67
The Contribution of Non-Dopaminergic Pathology to Cognitive, Motor and Affective Disability in Parkinson’s Disease....Pages 69-76
Clinical, Pathological and Neurochemical Characteristics of Lewy Body Dementia....Pages 77-86
Creutzfeldt-Jakob Disease (CJD) is Not an Infectious Disease....Pages 87-93
Normal Production of the Amyloid ?-Protein and the Pathogenesis of Alzheimer’s Disease....Pages 95-97
Modulation of APP Processing by Neurotransmission....Pages 99-103
Amyloid Precursor Protein (APP) Gene Expression is Controlled by a NFkB/Rel Related Protein....Pages 105-110
Specific Cleavage of ?-Amyloid Precursor Protein by an Integral Membrane Metalloendopeptidase....Pages 111-118
Amyloidogenic Fragments of Amyloid Precursor Protein in Cells Cultured under Leupeptin....Pages 119-125
A Leptomeningeal Protease Releasing the ? Protein from the ? Protein Precursor of Alzheimer’s Disease....Pages 127-130
Cell Surface Receptor Mediated Control of Amyloid Precursor Protein Secretion: Involvement of Pleiotropic Signal Transduction Cascades....Pages 131-139
Role of ?-Amyloid in the Diagnosis of Neurodegenerative Diseases: Diffuse Lewy Body Disease Versus Alzheimer’s Disease....Pages 141-147
Identification and Role of Non-Beta Components of Senile Plaque Amyloid in Alzheimer’s Disease....Pages 149-155
Metabolic and Functional Changes in ?APP Overexpressing Mouse Neuronal Cell Line: Muscarinic Receptor-Mediated Calcium Influx....Pages 157-163
Effect of Ciliary Neurotrophic Factor on ?-Amyloid Precursor Protein mRNA Expression....Pages 165-170
Tau and High Molecular Weight Microtubule Associated Proteins in Aluminum-Induced Neurofibrillary Pathology....Pages 171-175
Phenotypes and Genotypes of Apolipoprotein E in Japanese Patients with Late-Onset Sporadic Alzheimer’s Disease, Vascular Dementia, Down’s Syndrome or Parkinson’s Disease....Pages 177-188
Risk Factors of Senile Dementias: Comparisons of Alzheimer’s Disease and Vascular Dementias....Pages 189-196
Predictors of Institutional Care in Parkinson’s Disease....Pages 197-201
Parkinson’s Disease: Biometrics Towards Nature-Nurture Puzzles....Pages 203-204
Pathogenesis of Nigral Cell Death in Parkinson’s Disease....Pages 205-210
Complement Components and GFAP Immunoreactivity within Alzheimer and Pathologic Aged Cortex....Pages 211-216
Aluminum Neurotoxicity and Alzheimer’s Disease....Pages 217-222
Distribution and Regulation of Interleukin 1-? Converting Enzyme in Rat and Man....Pages 223-229
Localization and Density of Transferrin Binding Sites in the Nigrostriatal System of Control Subjects and Patients with Parkinson’s Disease....Pages 231-238
Positron Emission Tomography (PET) Studies with Ligands for Cholinergic Receptors in the Human Brain....Pages 239-244
Effect of Cholinergic Enhancers on Basal Forebrain Function Governing Cortical Cerebral Blood Flow....Pages 245-249
Acetylcholinesterase is Not a Protease: Implications for Alzheimer’s Disease....Pages 251-257
Does Tacrine Increase Acetylcholine Release from the Hippocampus?....Pages 259-266
Aging-Induced Changes in the Autoregulation of Acetylcholine Release in the Rat Brain....Pages 267-273
The Effect of Acetylcholinesterase Inhibitors on Acetylcholinesterase in Senile Plaque, Normal Human or Rat Brain, Human Erythrocyte or Rat Skeletal Muscle....Pages 275-282
Quantity and Quality Changes of G Protein in Dementia of the Alzheimer Type....Pages 283-290
Calcium Binding Proteins in the Septo-Hippocampal System of the Aged Rat....Pages 291-296
Calcium Binding Proteins Differentiate Midbrain Dopaminergic Systems in Humans....Pages 297-302
Enzymatic and Genetic Analysis of Cu/Zn Superoxide Dismutase in Non-Familial Alzheimer’s Disease....Pages 303-306
Oxidative Stress and the Loss of Receptor Sensitivity in Aging....Pages 307-309
Oxygen Toxicity Induces Apoptotic Neuronal Death in Cultured Rat Hippocampal Neurons....Pages 311-317
Histochemical Demonstration of Monoamine Oxidase Activity in the Mouse Striatal Cholinergic Neurons and Marked Species Variations among Rodent Striata....Pages 319-326
Cell Wall-Defective Forms of Nocardia Asteroides Require Tetrahydrobiopterin for Their Growth....Pages 327-331
The Cholinotoxin AF64A Differentially Attenuates in Vitro Transcription of the Human Cholinesterase Genes....Pages 333-337
Transient Alterations in the in Vivo Levels of Cholinesterase mRNAS Suggest Differential Adjustment to Cholinotoxic Stimuli....Pages 339-345
Failure of the Neurotrophic ACTH(4–10) Analogue (BIM 22015) to Attenuate the AF64A-Induced Cholinergic Lesion in Rat Hippocampus....Pages 347-352
Combined Nicotinic and Muscarinic Cholinergic and Serotonergic Blockade Selectively Impair Acquisition of Spatial Navigation....Pages 353-358
Effect of JTP-2942, a Novel TRH Analogue, on Cognitive Function and Learning in Rodents....Pages 359-369
Effects of a Novel TRH Analog, JTP-2942, on Cholinergic and Monoaminergic Neurons in the Brain....Pages 371-377
Effect of Cortical Ischemic Damage on Primate Nucleus Basalis....Pages 379-382
Intracerebroventricular Injection of Streptozotocin — An Animal Model for Sporadic Alzheimer’s Disease?....Pages 383-387
Neuropathological Studies on Strains of Senescence Accelerated Mouse with Age Related Deficits in Learning and Memory....Pages 389-393
Transgenic Rat and In-Vitro Studies of ?-Amyloid Precursor Protein Processing....Pages 395-400
“Kangenkaryu”, Chinese Herb Medicine, Improved Several Symptoms in Animal Models....Pages 401-409
Catecholamine-Containing Biodegradable Microsphere Implants: An Overview of Experimental Studies in Dopamine-Lesioned Rats....Pages 411-419
Alzheimer Disease: Major Neurotransmitter Deficits. Can they be Corrected?....Pages 421-427
Recent Clinical Trials of Cholinomimetics for Patients with Alzheimer’s Disease in Japan....Pages 429-436
New M1 Agonists: Selective Signaling, Neurotrophic-Like and Cognitive Effects — Implications in the Treatment of Alzheimer’s Disease....Pages 437-448
Xanomeline: A Potent and Selective M1 Muscarinic Agonist in Vitro....Pages 449-455
Absorption, Distribution, Metabolism, and Elimination of Radiolabeled Xanomeline in Healthy Male Subjects....Pages 457-461
Single and Multiple Dose Safety, Pharmacodynamics and Pharmacokinetics of Xanomeline, a Novel Muscarinic M1 Agonist in Healthy Male Subjects....Pages 463-468
Safety, Tolerance, and Pharmacokinetics of Xanomeline Tartrate: A Novel Muscarinic M1 Agonist in Healthy Elderly Subjects....Pages 469-473
The Safety and Tolerance of Xanomeline Tartrate, an M1-Specific Cholinergic Agonist, in Patients with Alzheimer’s Disease....Pages 475-478
CI-1002, a Novel Anticholinesterase and Muscarinic Antagonist....Pages 479-482
Preclinical Evaluation of Linopirdine: Neurochemical and Behavioral Effects....Pages 483-490
New Radioligands for PET-Examination of Central Muscarinic Receptors....Pages 491-498
Gangliosides and Alzheimer’s Disease....Pages 499-505
Estrogen in Clinical Trials for Dementia of Alzheimer Type....Pages 507-512
MDL 72,974 A a Novel MAO-B Inhibitor: A European Multicentre Trial in Parkinson’s Disease as an Adjunct to Levodopa....Pages 513-523
Neuronal Grafting in Parkinson’s Disease....Pages 525-530
Environmentally-Derived Carbolinium Analogs of MPP+ are Toxic to Dopaminergic Neurons in Vitro and in Vivo....Pages 531-535
Presence of N-Methylated ?-Carbolinium Ions and Potential Neurotoxic Analogs of MPP+ in the Brain and Cerebrospinal Fluid of Parkinsonian and Non-Parkinsonian Patients....Pages 537-543
Metabolic Bioactivation of Endogenous Isoquinolines as Dopaminergic Neurotoxins to Elicit Parkinson’s Disease....Pages 545-552
Effect of Selegiline Administration on the Urinary Excretion of Dopamine-Derived Tetrahydroisoquinoline Alkaloids in Parkinson’s Disease Patients....Pages 553-559
Inhibitory Effects of Endogenous Tetrahydroisoquinolines on Mitochondrial Respiration in Mouse Brain....Pages 561-567
Dopamine-Derived Isoquinolines as Dopaminergic Neurotoxins and Oxidative Stress....Pages 569-574
Effect of Chronic Administration of 1,2,3,4-Tetrahydroisoquinoline and Its Derivatives on the Monkey: Immunohistochemical Study....Pages 575-581
The in Vitro Formation of 1,3-Dimethyl-1,2,3,4-Tetrahydroisoquinoline, a Neurotoxic Metabolite of Amphetamines....Pages 583-587
A Novel Endogenous Amine, 1-Benzyl-1,2,3,4-Tetrahydroisoquinoline(1BnTIQ) in Parkinsonian CSF, and Its Toxicological Effect....Pages 589-597
Neurotrophic Factor Therapy of Alzheimer’s Disease....Pages 599-604
Potential Therapeutic Use of BDNF or NT-4/5 in Parkinson’s and Alzheimer’s Diseases....Pages 605-609
Loss of Growth Inhibitory Factor in Degenerative Disease....Pages 611-619
NGF Rescues Cholinergic Cell Bodies of the Primate Nucleus Basalis of Meynert and Induces Compensatory Synaptic Changes in Cortically-Lesioned Rats....Pages 621-624
Indicators of Oxidative Stress in Aged Fischer 344 Rats: Potential for Neurotrophic Treatment....Pages 625-632
Regulation of Expression of the Low-Affinity NGF Receptor (p75LNGFR) Gene in Clonal Rat Pheochromocytoma PC12h-R Cells and Cultured Rat Basal Forebrain Cholinergic Neurons: Its Relation to Expression of the High-Affinity NGF Receptor (trkA) Gene....Pages 633-640
Molecular Biology of Catecholamine Systems: Multiple Tyrosine Hydroxylases in Different Simian Species, and in Humans in Relation to Parkinson’s Disease....Pages 641-646
Population Diversity of Point Mutations in the Human AChE and BCHE Genes Predicts Variable Responses to Anticholinesterase Drugs....Pages 647-654
Inhibition of Excitatory Amino Acid-Induced Neurotoxicity by a Tau Antisense Oligonucleotide in Primary Culture of Cerebellar Granule Cells....Pages 655-659
Molecular Cloning of Human Growth Inhibitory Factor CDNA and Its Down-Regulation in Alzheimer’s Disease....Pages 661-667
Expression of Human Tyrosine Hydroxylase-Chloramphenicol Acetyltransferase (CAT) Fusion Gene in the Brains of Transgenic Mice as Examined by CAT Immunocytochemistry....Pages 669-675
Is the Point Mutation in Codon 331 of the Mitochondrial ND2 Gene Associated with Alzheimer’s Disease?....Pages 677-683
A Novel Gene Delivery System for Neuroactive Peptides in Brain Tissue....Pages 685-692
Back Matter....Pages 693-697
The Cholinergic Hypothesis of Geriatric Cognitive Dysfunction”: Consensus Meeting. January 24–25, 1993, Brescia, Italy....Pages 699-707
....Pages 713-724